Astrazeneca plc - ADR

Astrazeneca plc - ADR

AZN

Market Cap$209.68B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Astrazeneca plc - ADRAstrazeneca plc - ADR27.21.42%19%8.40.8

Earnings Call Q1 2025

April 29, 2025 - AI Summary

Strong Revenue Growth: AstraZeneca reported a total revenue growth of 10% in Q1 2025, with product sales increasing by 9%. Core operating profit rose by 12%, and core earnings per share (EPS) increased by 21%, aided by a lower tax rate due to settlements in certain jurisdictions.
Pipeline Development & Approvals: The company secured 13 approvals across key regions since February, with five positive Phase III results announced in recent months. AstraZeneca has set a goal to deliver at least 20 new medicines by 2030, having already approved nine, highlighting a robust pipeline that could drive future revenue growth.
Oncology & Hematology Performance: The Oncology business saw total revenues grow by 13% in Q1 to $5.6 billion, with strong performances from key products like Tagrisso and Calquence. Demand dynamics from Medicare Part D redesign began affecting performance, but volume growth is expected to continue supporting revenue in the sector.

Exclusive for Stockcircle Pro members

Sign upSign Up
$37.31

Current Fair Value

44.8% downside

Overvalued by 44.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$209.68 Billion
Enterprise Value$235.40 Billion
Dividend Yield$1.54 (1.42188169426426%)
Earnings per Share$1.14
Beta0.18
Outstanding Shares6,200,000,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio27.17
PEG72.95
Price to Sales8.45
Price to Book Ratio11.26
Enterprise Value to Revenue4.28
Enterprise Value to EBIT21.45
Enterprise Value to Net Income29
Total Debt to Enterprise0.13
Debt to Equity0.75

Revenue Sources

No data

Insider Trades

ESG Score

No data

About AstraZeneca Plc

CEO: Pascal Soriot

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...